Do analysts prefer BDRX or AIXC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, BDRX or AIXC?

Biodexa Pharmaceuticals has higher revenue and earnings than Qualigen Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals $470K 14.60 -$8.42M N/A N/A Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A

Is BDRX or AIXC more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A Qualigen Therapeutics N/A -771.52% -79.52%

Do analysts prefer BDRX or VTGN?

VistaGen Therapeutics has a consensus price target of $0.95, suggesting a potential upside of 65.05%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe VistaGen Therapeutics is more favorable than Biodexa Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 VistaGen Therapeutics 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Which has preferable valuation & earnings, BDRX or VTGN?

Biodexa Pharmaceuticals has higher earnings, but lower revenue than VistaGen Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals $470K 14.60 -$8.42M N/A N/A VistaGen Therapeutics $490K 46.54 -$51.42M -$1.89 N/A

Is BDRX or VTGN more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat VistaGen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A VistaGen Therapeutics N/A -109.72% -89.62%

Do analysts rate PLUR or BDRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, PLUR or BDRX?

Biodexa Pharmaceuticals has lower revenue, but higher earnings than Pluri. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pluri $1.34M 19.16 -$22.58M -$4.53 N/A Biodexa Pharmaceuticals $470K 14.60 -$8.42M N/A N/A

Is PLUR or BDRX more profitable?

Biodexa Pharmaceuticals has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Company Net Margins Return on Equity Return on Assets Pluri -2,162.08% N/A -106.59% Biodexa Pharmaceuticals N/A N/A N/A

Do analysts prefer CLRB or BDRX?

Cellectar Biosciences currently has a consensus target price of $11.00, suggesting a potential upside of 300.00%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cellectar Biosciences is more favorable than Biodexa Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, CLRB or BDRX?

Biodexa Pharmaceuticals has higher revenue and earnings than Cellectar Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A Biodexa Pharmaceuticals $470K 14.60 -$8.42M N/A N/A

Is CLRB or BDRX more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -349.24% -153.18% Biodexa Pharmaceuticals N/A N/A N/A

Do analysts prefer BDRX or BCTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, BDRX or BCTX?

Biodexa Pharmaceuticals has higher revenue and earnings than Briacell Therap. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals $470K 14.60 -$8.42M N/A N/A Briacell Therap N/A N/A -$26.31M -$23.33 N/A

Is BDRX or BCTX more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A Briacell Therap N/A -173.08% -139.64%

Biodexa Pharmaceuticals (BDRX) Competitors

$3.43 -0.16 (-4.46%)

Closing price 03:59 PM Eastern

Extended Trading

$3.48 +0.05 (+1.46%)

As of 04:15 PM Eastern

Compare

BDRX vs. AIXC, VTGN, PLUR, CLRB, and BCTX

Should you buy Biodexa Pharmaceuticals stock or one of its competitors? MarketBeat compares Biodexa Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biodexa Pharmaceuticals include Qualigen Therapeutics (AIXC), VistaGen Therapeutics (VTGN), Pluri (PLUR), Cellectar Biosciences (CLRB), and Briacell Therap (BCTX). These companies are all part of the "pharmaceutical products" industry.

How does Biodexa Pharmaceuticals compare to Qualigen Therapeutics?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

Biodexa Pharmaceuticals has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

In the previous week, Qualigen Therapeutics had 1 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 1 mentions for Qualigen Therapeutics and 0 mentions for Biodexa Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 1.89 beat Qualigen Therapeutics' score of 0.93 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Very Positive
Qualigen Therapeutics	Positive

Biodexa Pharmaceuticals has higher revenue and earnings than Qualigen Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	$470K	14.60	-$8.42M	N/A	N/A
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biodexa Pharmaceuticals' return on equity of 0.00% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
Qualigen Therapeutics	N/A	-771.52%	-79.52%

17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by company insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Biodexa Pharmaceuticals beats Qualigen Therapeutics on 7 of the 9 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to VistaGen Therapeutics?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

In the previous week, VistaGen Therapeutics had 1 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 1 mentions for VistaGen Therapeutics and 0 mentions for Biodexa Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 1.89 beat VistaGen Therapeutics' score of 0.94 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Very Positive
VistaGen Therapeutics	Positive

Biodexa Pharmaceuticals has higher earnings, but lower revenue than VistaGen Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	$470K	14.60	-$8.42M	N/A	N/A
VistaGen Therapeutics	$490K	46.54	-$51.42M	-$1.89	N/A

17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by company insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Biodexa Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

VistaGen Therapeutics has a consensus price target of $0.95, suggesting a potential upside of 65.05%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe VistaGen Therapeutics is more favorable than Biodexa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Biodexa Pharmaceuticals' return on equity of 0.00% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
VistaGen Therapeutics	N/A	-109.72%	-89.62%

Summary

VistaGen Therapeutics beats Biodexa Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Pluri?

Pluri (NASDAQ:PLUR) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Pluri has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, Biodexa Pharmaceuticals has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

Biodexa Pharmaceuticals has lower revenue, but higher earnings than Pluri.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.34M	19.16	-$22.58M	-$4.53	N/A
Biodexa Pharmaceuticals	$470K	14.60	-$8.42M	N/A	N/A

Biodexa Pharmaceuticals has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
Biodexa Pharmaceuticals	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Pluri had 4 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 4 mentions for Pluri and 0 mentions for Biodexa Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 1.89 beat Pluri's score of 0.59 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Pluri	Positive
Biodexa Pharmaceuticals	Very Positive

16.6% of Pluri shares are held by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 43.2% of Pluri shares are held by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Biodexa Pharmaceuticals beats Pluri on 6 of the 10 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

Cellectar Biosciences has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Biodexa Pharmaceuticals has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market.

Cellectar Biosciences currently has a consensus target price of $11.00, suggesting a potential upside of 300.00%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cellectar Biosciences is more favorable than Biodexa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biodexa Pharmaceuticals' return on equity of 0.00% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
Biodexa Pharmaceuticals	N/A	N/A	N/A

16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 2.6% of Cellectar Biosciences shares are held by insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Cellectar Biosciences had 3 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 3 mentions for Cellectar Biosciences and 0 mentions for Biodexa Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 1.89 beat Cellectar Biosciences' score of 0.77 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Cellectar Biosciences	Positive
Biodexa Pharmaceuticals	Very Positive

Biodexa Pharmaceuticals has higher revenue and earnings than Cellectar Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
Biodexa Pharmaceuticals	$470K	14.60	-$8.42M	N/A	N/A

Summary

Biodexa Pharmaceuticals beats Cellectar Biosciences on 7 of the 12 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Briacell Therap?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Briacell Therap (NASDAQ:BCTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Biodexa Pharmaceuticals has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market.

Biodexa Pharmaceuticals has higher revenue and earnings than Briacell Therap.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	$470K	14.60	-$8.42M	N/A	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.4% of Briacell Therap shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of Briacell Therap shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Biodexa Pharmaceuticals' return on equity of 0.00% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
Briacell Therap	N/A	-173.08%	-139.64%

In the previous week, Briacell Therap had 3 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 3 mentions for Briacell Therap and 0 mentions for Biodexa Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 1.89 beat Briacell Therap's score of 0.47 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Very Positive
Briacell Therap	Neutral

Summary

Biodexa Pharmaceuticals beats Briacell Therap on 7 of the 9 factors compared between the two stocks.

Get Biodexa Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDRX vs. The Competition

Export

Metric	Biodexa Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.86M	$3.35B	$6.44B	$12.47B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	N/A	18.72	23.87	24.40
Price / Sales	14.60	320.32	521.86	117.01
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	0.03	6.80	9.99	6.73
Net Income	-$8.42M	$24.09M	$3.56B	$337.03M
7 Day Performance	2.08%	-2.48%	-0.87%	0.11%
1 Month Performance	N/A	N/A	N/A	-1.70%
1 Year Performance	-94.09%	48.95%	28.77%	34.24%

Biodexa Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDRX Biodexa Pharmaceuticals	0.7955 of 5 stars	$3.43 -4.5%	N/A	-93.8%	$6.86M	$470K	N/A	20	Positive News Gap Up
AIXC Qualigen Therapeutics	0.5126 of 5 stars	$1.28 -0.8%	N/A	N/A	$26.10M	N/A	N/A	50	High Trading Volume
VTGN VistaGen Therapeutics	2.627 of 5 stars	$0.64 -1.6%	$0.95 +49.2%	-76.6%	$25.63M	$789K	N/A	40
PLUR Pluri	0.9376 of 5 stars	$2.31 -2.5%	$12.00 +419.5%	-46.6%	$25.61M	$1.34M	N/A	150	Analyst Upgrade Gap Up
CLRB Cellectar Biosciences	3.7688 of 5 stars	$3.10 -3.1%	$11.00 +254.8%	-68.8%	$25.57M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDRX) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biodexa Pharmaceuticals (BDRX) Competitors

BDRX vs. AIXC, VTGN, PLUR, CLRB, and BCTX

How does Biodexa Pharmaceuticals compare to Qualigen Therapeutics?

Summary

How does Biodexa Pharmaceuticals compare to VistaGen Therapeutics?

Summary

How does Biodexa Pharmaceuticals compare to Pluri?

Summary

How does Biodexa Pharmaceuticals compare to Cellectar Biosciences?

Summary

How does Biodexa Pharmaceuticals compare to Briacell Therap?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX vs. The Competition

Biodexa Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biodexa Pharmaceuticals (BDRX) Competitors

BDRX vs. AIXC, VTGN, PLUR, CLRB, and BCTX

How does Biodexa Pharmaceuticals compare to Qualigen Therapeutics?

Which has more risk and volatility, BDRX or AIXC?

Does the media favor BDRX or AIXC?

Which has better valuation and earnings, BDRX or AIXC?

Do analysts prefer BDRX or AIXC?

Is BDRX or AIXC more profitable?

Do insiders & institutionals have more ownership in BDRX or AIXC?

Summary

How does Biodexa Pharmaceuticals compare to VistaGen Therapeutics?

Does the media refer more to BDRX or VTGN?

Which has preferable valuation & earnings, BDRX or VTGN?

Do insiders & institutionals have more ownership in BDRX or VTGN?

Which has more risk & volatility, BDRX or VTGN?

Do analysts prefer BDRX or VTGN?

Is BDRX or VTGN more profitable?

Summary

How does Biodexa Pharmaceuticals compare to Pluri?

Which has more volatility & risk, PLUR or BDRX?

Which has preferable earnings & valuation, PLUR or BDRX?

Is PLUR or BDRX more profitable?

Do analysts rate PLUR or BDRX?

Does the media refer more to PLUR or BDRX?

Do insiders & institutionals have more ownership in PLUR or BDRX?

Summary

How does Biodexa Pharmaceuticals compare to Cellectar Biosciences?

Which has more volatility & risk, CLRB or BDRX?

Do analysts prefer CLRB or BDRX?

Is CLRB or BDRX more profitable?

Do institutionals & insiders believe in CLRB or BDRX?

Does the media refer more to CLRB or BDRX?

Which has stronger earnings and valuation, CLRB or BDRX?

Summary

How does Biodexa Pharmaceuticals compare to Briacell Therap?

Which has more risk and volatility, BDRX or BCTX?

Which has preferable earnings and valuation, BDRX or BCTX?

Do analysts prefer BDRX or BCTX?

Do institutionals and insiders hold more shares of BDRX or BCTX?

Is BDRX or BCTX more profitable?

Does the media favor BDRX or BCTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX vs. The Competition

Biodexa Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools